Angiogenesis is essential for the development and growth of tumors. It is a highly regulated
process that requires cross‐talk between signaling pathways at all stages of blood vessel …

Tyrosine kinase receptors (TKRs) play a key role in tumour cell proliferation and survival
since they are involved in endothelial cell activation leading to tumour neoangiogenesis. In …

Background Sunitinib has shown single-agent activity in patients with previously treated
metastatic breast cancer (MBC). We investigated the safety of the combination of sunitinib …

Purpose Sunitinib in combination with docetaxel enhances antitumor activity in xenograft
models of human breast and non-small cell lung cancer. We assessed the maximum …

Angiogenesis is an important component of cancer growth, invasion and metastasis.
Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We …

Our understanding of the molecular heterogeneity and pathogenesis of breast cancer has
led to significant improvements in patients' survival. The observation of steroid hormone …

Sunitinib malate (SU11248) is a multitarget oral tyrosine kinase receptor (RTKs) inhibitor
which was approved by FDA in renal cells carcinoma (RCC) and imatinib-resistant or …

Angiogenesis plays a central role in the development of metastasis in breast cancer. Recent
results of large randomized trials show clinically significant improvements in outcomes with …

Sunitinib malate (SUTENT®) is an oral, multitargeted tyrosine kinase inhibitor that blocks
several pathways central to angiogenesis and tumor cell proliferation and migration …

Preclinical and clinical trials suggest that tyrosine kinase inhibitors (TKI) could supplement
current therapies in metastatic breast cancer (MBC). HER-2 inhibition is still a main focus …